Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial.

"Declarations Ethics approval and consent to participateThe authors assert that all procedures used in the conduct of this study conformed to the ethical standards of the relevant national and institutional committees on human experimentation and to the 1975 Declaration of Helsinki, as revised in 2008. The research ethics committee of Alborz University of Medical Sciences approved all procedures involving human subjects/patients in this study with the number of the code of ethics IR.ABZUMS.REC.1400.275 and the registration code number IRCT20200805048313N1that are related to the registration of the study protocol of Iranian clinical trials. The registration date of this study is February 10, 2022. A written consent form was obtained from all participants before entering the study. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work was supported by the Alborz University of Medical Sciences under Grant IR.ABZUMS.REC.1400.275."

"Declarations: Ethics approval and consent to participateThe authors assert that all procedures used in the conduct of this study conformed to the ethical standards of the relevant national and institutional committees on human experimentation and to the 1975 Declaration of Helsinki, as revised in 2008. The research ethics committee of Alborz University of Medical Sciences approved all procedures involving human subjects/patients in this study with the number of the code of ethics IR.ABZUMS.REC.1400.275 and the registration code number IRCT20200805048313N1that are related to the registration of the study protocol of Iranian clinical trials. The registration date of this study is February 10, 2022. A written consent form was obtained from all participants before entering the study.: Consent for publicationNot applicable.: Competing interestsThe authors declare no competing interests. Ethics approval and consent to participate: The authors assert that all procedures used in the conduct of this study conformed to the ethical standards of the relevant national and institutional committees on human experimentation and to the 1975 Declaration of Helsinki, as revised in 2008. The research ethics committee of Alborz University of Medical Sciences approved all procedures involving human subjects/patients in this study with the number of the code of ethics IR.ABZUMS.REC.1400.275 and the registration code number IRCT20200805048313N1that are related to the registration of the study protocol of Iranian clinical trials. The registration date of this study is February 10, 2022. A written consent form was obtained from all participants before entering the study."